Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

AGM Statement

8 Sep 2011 07:00

RNS Number : 8405N
Immunodiagnostic Systems Hldgs PLC
08 September 2011
 



 

 

Immunodiagnostic Systems Holdings plc

("IDS" or "the Company")

 

AGM Statement

 

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, will hold its Annual General Meeting today at 3.00pm at the offices of Brewin Dolphin Limited at 12 Smithfield Street, London EC1A 9BD.

 

At the meeting Chairman, David Evans, will make the following statement to shareholders:

 

"Revenues to 31 August are £22.6m compared with £18.4m for the comparative period in 2010. We have seen continued growth in our IDS-iSYS revenues which have grown £4.4m over the comparative period. As of 31 August 299 instruments have been sold or placed an increase of 58 systems since the year end and we anticipate a further 15 instruments being placed or sold in September. Average revenue per instrument is £88k compared to £72k in August 2010.

 

Our revenues are traditionally weighted to the second-half of the year and we believe this year that the trend ratio will be higher this financial year reflecting both a seasonally quieter July and August and also higher anticipated reagent / instrument sales pull-through and the anticipated continued resilience of manual product sales in the second-half.

 

The process of transition in terms of the Board has continued since the year end. We have added Roland Sackers, the CFO of QIAGEN N.V. and at the end of this meeting Anthony Martin, who has a long-established track record in the diagnostics and life sciences space, will succeed me as Chairman.

We remain active in examining the potential for licensing-out our automated IDS-iSYS platform into other disease areas not served by the Company and which can help drive value. We have ongoing discussions in autoimmune disease and in coagulation testing outside of Europe and we will keep you updated as discussions progress.

 

Finally we continue to seek acquisitions where we believe we can either add value to our existing franchise in bone and mineral disease or where we can validly exploit the IDS-iSYS asset base.

 

A more detailed trading update will be given week commencing 3rd October."

 

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel: 0191 519 0660

Ian Cookson, Chief Executive Officer

Paul Hailes, Finance Director

 

 

 

Brewin Dolphin

Tel: 0845 213 4930

Matt Davis

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSSAFWWFFSEFU
Date   Source Headline
17th May 20217:00 amRNSOffer for Immunodiagnostic Systems Holdings Plc
16th Apr 20217:00 amRNSFY21 Trading Update
29th Mar 20217:00 amRNSFDA EUA for automated IgG SARS-CoV-2 assay
27th Nov 20209:05 amRNSSecond Price Monitoring Extn
27th Nov 20209:00 amRNSPrice Monitoring Extension
27th Nov 20207:00 amRNSLaunch of SARS-CoV-2 Antigen Rapid Tests
20th Nov 20206:22 pmRNSInterim Results - period ended 30 September 2020
26th Oct 20209:05 amRNSSecond Price Monitoring Extn
26th Oct 20209:00 amRNSPrice Monitoring Extension
23rd Oct 20204:35 pmRNSH1 Trading Update
9th Oct 20207:00 amRNSAssay to detect IgM SARS-CoV-2 antibodies launch
16th Sep 20207:00 amRNSNew TDM assays launched for use on the IDS-iSYS
14th Sep 20202:39 pmRNSDirector/PDMR Shareholding
27th Aug 20207:00 amRNSSARS-CoV-2 manufacturing agreement
13th Aug 20204:40 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:00 amRNSAutomated IgM assay to detect SARS-CoV-2
4th Aug 20204:18 pmRNSLaunch of automated IDS Cortisol assay
23rd Jul 20202:57 pmRNSResults of AGM
23rd Jul 20207:00 amRNSAGM Statement
17th Jul 202010:40 amRNSDirector/PDMR Shareholding
16th Jul 20201:45 pmRNSDirector/PDMR Shareholding
30th Jun 20209:05 amRNSSecond Price Monitoring Extn
30th Jun 20209:00 amRNSPrice Monitoring Extension
30th Jun 20207:00 amRNSLaunch of assay to detect SARS-CoV-2 antibodies
17th Jun 20208:35 amRNSPublication of Annual Report and Accounts
17th Jun 20207:00 amRNSFinal Results
12th Jun 20209:06 amRNSSecond Price Monitoring Extn
12th Jun 20209:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSAutomated assay to detect SARS-CoV-2 antibodies
17th Apr 20204:35 pmRNSFY20 Trading Update
31st Mar 202011:00 amRNSDirector/PDMR Shareholding
21st Feb 20204:11 pmRNSDirector/PDMR Shareholding
21st Feb 20209:11 amRNSDirector/PDMR Shareholding
20th Feb 20204:49 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:35 pmRNSHalf-year Report
18th Oct 20194:35 pmRNSTrading Statement
25th Jul 20193:34 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement
11th Jul 20192:16 pmRNSDirector/PDMR Shareholding
5th Jul 201910:02 amRNSDirector/PDMR Shareholding
19th Jun 20197:05 amRNSPublication of Annual Report and Accounts
19th Jun 20197:00 amRNSFinal Results
22nd May 20192:05 pmRNSSecond Price Monitoring Extn
22nd May 20192:00 pmRNSPrice Monitoring Extension
18th Apr 20194:35 pmRNSFY2019 Trading Update
12th Mar 201911:55 amRNSChange of Auditor
7th Jan 20198:20 amRNSDirector/PDMR Shareholding
18th Dec 20181:42 pmRNSDirector/PDMR Shareholding
6th Dec 20185:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.